Alterity Receives Positive FDA Feedback on CMC Meeting
Filed with ASX · · 3 pages · English
Alterity Therapeutics Ltd. on 6ix
Story so far
Earlier from Alterity Therapeutics
- Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
- Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors
- Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting
- Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy
- Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
Later from Alterity Therapeutics
- Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
- Notice of General Meeting/Proxy Form
- Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
- Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
- Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics